Health ConditionsThe World Health Organization (WHO) and the 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) define COPD as "a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, expectoration, exacerbations) due to abnormalities of the airway (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction."
COPD is one of the leading global causes of morbidity and mortality, with a hallmark of progressive airflow obstruction primarily caused by cigarette smoke. The global prevalence of COPD oscillates around 12% of the general population, and it currently ranks as the third cause of mortality in the world, responsible for approximately 3 million deaths, just behind cardiovascular diseases. The prevalence and burden of COPD are projected to increase over the coming decades due to a combination of continued exposure to COPD risk factors and aging of the world's population.
COPD is a mixture of distinct disease processes — chronic bronchitis, emphysema, and to a lesser extent asthma — that together form the complete clinical and pathophysiological picture. Chronic bronchitis is defined by excessive mucus production with airway obstruction and notable hyperplasia of mucus-producing glands; damage to the endothelium impairs the mucociliary response that clears bacteria and mucus, and inflammation and secretions provide the obstructive component. Emphysema results from destruction of alveolar walls, leading to reduced gas exchange, permanent airspace enlargement, loss of elastic recoil, hyperinflation, and expiratory flow limitation; as a consequence of fiber destruction by metalloproteinases, there are changes in collagen- and elastic-fiber organization, affecting the lung's tissue stability and mechanical properties and contributing to lung function decline over time.
COPD is a group of lung diseases that worsen over time; the condition may affect the lungs and other parts of the body, leading to difficulties breathing, coughing, and wheezing, and may also lead to other health complications ranging from weight loss to fatigue and lightheadedness.
The pathogenic mechanisms of COPD result in physiological abnormalities including mucous hypersecretion and ciliary dysfunction, airflow obstruction and hyperinflation, gas exchange abnormalities, pulmonary hypertension, and systemic effects. Mucous hypersecretion results in a chronic productive cough.
Although COPD primarily affects the lung, it is often accompanied by extrapulmonary manifestations such as weight loss and malnutrition, skeletal muscle dysfunction, and an excess of harmful oxidants, which can lead to a decline in quality of life and possible death. Systemic inflammation and skeletal muscle wasting contribute to limiting exercise capacity and worsen prognosis irrespective of the degree of airflow obstruction; patients also have an increased risk of cardiovascular disease associated with an increase in C-reactive protein.
Cigarette smoke exposure causes an imbalance favoring pro- over antioxidants (oxidative stress), leading to transcription factor activation and increased expression of inflammatory mediators and proteases; different cell types, including macrophages, epithelial cells, neutrophils, and T lymphocytes, contribute to COPD pathophysiology, and alteration in cell functions results in the generation of an oxidative and inflammatory microenvironment, which contributes to disease progression.
Besides inflammation, two other processes are involved in the pathogenesis of COPD: an imbalance between proteases and antiproteases and an imbalance between oxidants and antioxidants (oxidative stress) in the lungs. Inflammation is present in the lungs, particularly the small airways, of all people who smoke; this normal protective response to inhaled toxins is amplified in COPD, leading to tissue destruction, impairment of the defence mechanisms that limit such destruction, and disruption of repair mechanisms, and the inflammatory and structural changes generally increase with disease severity and persist even after smoking cessation.
COPD is characterized by progressive airflow limitation due to chronic inflammation in the bronchi, and mechanisms of the innate immune system are involved in various links in the pathogenesis. Evidence is particularly strong for a role for B cells in emphysema pathogenesis, possibly facilitated by the appearance within the distal lung parenchyma of organized lymphoid follicles containing germinal centers that permit production of high-affinity antibodies.
Dynamic hyperinflation results in diaphragm mechanical disadvantage leading to dysfunction; clinical studies using ultrasonography in in-hospital patients have shown its ability to detect diaphragm weakness, resulting in increased hospital length of stay. Because of low cardiac output, the rest of the body also suffers from tissue hypoxia and pulmonary cachexia; these patients may develop muscle wasting and weight loss.
A hallmark of COPD is progressive airflow obstruction primarily caused by cigarette smoke. The prevalence of COPD is often directly related to the prevalence of tobacco smoking, but in many countries outdoor, occupational, and household air pollution resulting from the burning of wood and other biomass fuels are also important COPD risk factors.
Among environmental risk factors associated with development of COPD, mention has been made of exposure to biomass fumes, occupational exposure to dust and fumes (in agriculture, animal husbandry, mining, construction, exposure to chemical products in industry), environmental pollution, exposure to passive smoking, chronic asthma, and tuberculosis. Strong evidence indicates that daily variation in exposure to outdoor air pollution correlates with acute exacerbations of COPD.
Variants in the SERPINA1 gene cause alpha-1 antitrypsin deficiency; this gene provides instructions for making a protein called alpha-1 antitrypsin, which protects the body from a powerful enzyme called neutrophil elastase that, if not tightly controlled, can attack normal tissues, especially the lungs. Alpha-1 antitrypsin deficiency occurs worldwide, but its prevalence varies by population; it affects about 1 in 1,500 to 3,500 individuals with European ancestry and is uncommon in people of Asian descent. Many individuals with alpha-1 antitrypsin deficiency are likely undiagnosed, particularly people with COPD; COPD can be caused by alpha-1 antitrypsin deficiency, but the underlying genetic condition is often never diagnosed.
Rather than a single cause, development and progression of COPD likely involve both complex gene-by-environment interactions to multiple inhalational exposures and a variety of molecular pathways.
Exacerbation history is the strongest predictor of future exacerbations, with 34 studies reporting a significant association between history of exacerbations and risk of future moderate or severe exacerbations; other significant risk factors identified in multiple studies included disease severity, comorbidities, higher symptom burden, and higher blood eosinophil count.
COPD patients face increased metabolic demands, systemic inflammation, and reduced dietary intake, resulting in muscle wasting, sarcopenia, and cachexia. COPD patients often present with malnutrition, sarcopenia, and osteoporosis with possible onset of cachexia, with an inadequate dietary intake and a poor quality of life. Diet plays a pivotal role in patients with COPD through three mechanisms: regulation of carbon dioxide produced/oxygen consumed, inflammation, and oxidative stress.
Correcting malnutrition is an important part of maintenance therapy for COPD and has been shown to improve exercise tolerance, quality of life, and survival in patients.
Scientific Evidence: Numerous studies have revealed the benefits of a diet rich in antioxidants in COPD, including vitamins A, C, and E, beta-carotene, and micronutrients such as magnesium, selenium, and zinc.
Very strong evidence exists for a positive effect of vitamins C, E, and β-carotene on the risk of COPD in the general population. However, despite lower dietary intake and blood levels of vitamins in patients with COPD than in control subjects, the effect on pulmonary function decline has not yet been longitudinally investigated in these patients.
Supplementation of vitamins C and E alone did not have a significant promoting effect on lung function in a systematic review and meta-analysis of micronutrient supplementation in COPD patients. The overall evidence for antioxidant vitamins is therefore stronger for dietary intake and risk reduction than for supplementation as a standalone intervention.
Scientific Evidence: Acute exacerbations in COPD patients are primarily caused by various bacterial and viral infections, and vitamin D deficiency can increase the risk of infections as well as chronic inflammation, which is extremely dangerous for severely ill COPD patients with low forced expiratory volume in one second (FEV₁) values.
Findings from a synthesis of four systematic reviews with meta-analyses and one recent RCT indicate that vitamin D supplementation does not generally reduce exacerbation rates in COPD patients; however, in patients with baseline 25-hydroxyvitamin D (25(OH)D) serum levels below 10 ng/mL, one meta-analysis reported a significant reduction in moderate-to-severe exacerbations following supplementation. Variability in study designs, dosages, and follow-up durations limit the generalizability of these findings; nonetheless, clinical guidelines recommend screening and supplementing vitamin D in COPD patients, particularly those with severe deficiency.
A meta-analysis of individual participant data from four RCTs (560 participants total) showed that supplementation did not influence the overall rate of moderate/severe COPD exacerbations (adjusted incidence rate ratio 0.94, 95% CI 0.78 to 1.13), but vitamin D supplementation safely and substantially reduced the rate of moderate/severe COPD exacerbations in patients with baseline 25-hydroxyvitamin D levels below 25 nmol/L.
A separate meta-analysis showed that supplementation of vitamin D alone had a certain improvement effect on lung function and immunity in COPD patients, such as FEV₁ and FEV₁/FVC, reduced the number of acute exacerbations, and improved the levels of T cells. The evidence is thus strongest in the subgroup of COPD patients with severe vitamin D deficiency; benefit in replete patients remains unproven.
Scientific Evidence: In stable COPD, higher levels of circulating inflammatory parameters (such as IL-6, CRP) were associated with higher omega-6 intake, whereas lower serum levels of TNF-α were significantly correlated with omega-3 PUFA intake. In an RCT involving 86 COPD patients, one group received omega-3, vitamin D, and leucine supplementation combined with high-intensity exercise for four months; their results after four months were significant in terms of exercise tolerance, weight gain, serum vitamin D levels, and eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) levels.
Omega-3 polyunsaturated fatty acids, including EPA and DHA, appear to have anti-inflammatory effects; however, there is contradictory evidence regarding the inverse association between intake of omega-3 PUFAs and the risk of COPD and mortality, and these findings have not yet been quantified in a comprehensive pooled meta-analysis. Conversely, the high saturated fat intake characteristic of a Western-type diet may exacerbate airway inflammation in chronic respiratory patients. Overall, evidence for omega-3 supplementation in COPD is preliminary and mixed; well-powered, long-term RCTs are needed.
Traditional/Historical Context: N-acetylcysteine is a semi-synthetic derivative of the amino acid cysteine, developed in the 1960s for use as a mucolytic and antioxidant agent. It was adopted in European clinical practice as an oral mucolytic for chronic bronchitis before the COPD concept was fully standardized.
Scientific Evidence: Cigarette smoke-induced oxidative stress is intimately associated with the progression and exacerbation of COPD, and among the various antioxidants studied, thiol antioxidants and mucolytic agents such as N-acetyl-L-cysteine have been reported to increase intracellular thiol status along with induction of glutathione (GSH) biosynthesis, leading to detoxification of free radicals and oxidants and inhibition of inflammatory responses.
The HIACE trial, conducted in Hong Kong on 120 patients randomly assigned to take NAC 600 mg twice daily or placebo plus usual therapy for one year, found that the frequency of COPD exacerbations with NAC was significantly lower than with placebo, and the value of mean forced expiratory flow (FEF25-75) was slightly but significantly increased in the NAC group.
A meta-analysis of 13 studies showed that overall, treatment with low and high doses of NAC significantly reduced the frequency of exacerbations (relative risk 0.75, 95% CI 0.66–0.84; p<0.01). A retrospective analysis of the HIACE study suggests that high-dose NAC is mainly effective in the frequent exacerbator phenotype, regardless of symptoms.
However, findings are not uniformly positive. A large, multicentre double-blind RCT of 968 patients with mild-to-moderate COPD found that the difference between the N-acetylcysteine group and the placebo group in the annual rate of total exacerbation was not significant (0.65 vs. 0.72 per patient-year; relative risk 0.90; 95% CI 0.80–1.02; P = 0.10). The evidence for NAC is therefore mixed: meta-analyses pooling all dose levels show a statistically significant overall reduction in exacerbations, but a large recent high-quality RCT in mild-to-moderate COPD did not replicate this finding. Effects may depend on disease severity, phenotype, and dose.
Traditional Use: Curcumin, the principal bioactive compound of turmeric (Curcuma longa), has a centuries-long history in Ayurvedic and traditional Chinese medicine for inflammatory and respiratory conditions. Resveratrol is a stilbene found in grapes and red wine and is associated with traditional Mediterranean dietary patterns. Quercetin is a flavonoid widely distributed in fruits and vegetables and features prominently in traditional botanical and European herbal medicine as an anti-inflammatory agent.
Scientific Evidence: Dietary polyphenols including curcumin, resveratrol, and green tea catechins/quercetin have been reported to increase intracellular thiol status along with induction of glutathione biosynthesis, leading to detoxification of free radicals and inhibition of ongoing inflammatory responses.
A systematic review and meta-analysis of RCTs examining dietary supplementation with eight polyphenols — curcumin, resveratrol, anthocyanins, quercetin, salidroside, dietary beetroot juice, pomegranate juice, and adjunctive AKL1 treatment — across a total of 894 participants found that curcumin and salidroside can improve the course of COPD by regulating blood pressure, inflammation, and the coagulation pathway. However, the possible negative effects of anthocyanins warn against ingredient heterogeneity; curcumin (200–500 mg/day) and tanshinone are recommended as adjuvant treatment options for COPD, but blind combination should be avoided, and the safety of ingredients such as quercetin needs further verification.
The overall evidence base for polyphenol supplementation in COPD is preliminary. Mechanistic data are largely in vitro or from animal models; the clinical trial database is small in terms of total participant numbers, and studies are of short duration with heterogeneous endpoints. Long-term, adequately powered RCTs are lacking.
Scientific Evidence: The improvement in patients with COPD supplemented with magnesium may be reflected in reducing the patient's level of inflammation, while other mineral interventions alone in COPD patients have been sparsely described. Evidence at this time is limited and the field remains underpowered in human clinical trials.
Scientific Evidence: Numerous studies have identified benefits of a diet rich in micronutrients including selenium and zinc in COPD patients. One RCT cited in the European literature examined Echinacea purpurea combined with zinc, selenium, and vitamin C to alleviate COPD exacerbations, though the evidence from that single trial is insufficient for broad conclusions. The evidence base for zinc and selenium as standalone supplements in COPD remains limited and is largely embedded within broader micronutrient studies.
Scientific Evidence: Recent evidence highlights the efficacy of targeted nutritional strategies, including essential amino acid supplementation, omega-3 fatty acids, vitamin D, and antioxidants, in improving respiratory function, muscle strength, and patient well-being in COPD. COPD patients face increased metabolic demands, systemic inflammation, and reduced dietary intake, resulting in muscle wasting, sarcopenia, and cachexia; recent evidence highlights the efficacy of targeted nutritional strategies, including essential amino acid supplementation, in improving respiratory function, muscle strength, and patient well-being. However, long-term efficacy data remain limited.
Scientific Evidence: L-carnitine is a quaternary amine that mediates as an essential transport cofactor transporting fatty acids into the mitochondrial matrix and plays a critical role in fatty acid energy metabolism; it is a water-soluble, vitamin-like substance that occurs naturally in the human body; in COPD, cachexia and muscle weakness are common systemic clinical manifestations besides pulmonary symptoms. In vitro antioxidant properties of L-carnitine have been demonstrated, but clinical trial data specifically in COPD are limited.
Adhering to a healthy dietary pattern rich in vegetables, legumes, fruit, nuts, and whole grains appears to have advantageous impacts on preventing and treating COPD, while following an unhealthy dietary pattern rich in red and processed meat, saturated fats, sweets, and sugary drinks affects COPD negatively.
Adhering to Mediterranean, Dietary Approaches to Stop Hypertension (DASH), Prudent, Ketogenic, and high-protein dietary patterns may be related to a lower risk of COPD and improved pulmonary function.
The prudent dietary pattern — diets rich in fruits, vegetables, and whole grains — was associated with a lower risk of COPD, while Western-style diets — diets rich in processed meats, refined grains, desserts, and sweets — were associated with a higher risk of COPD.
Dietary patterns associated with benefits in prevention of the risk of respiratory diseases include those typical of the Mediterranean diet, while fast-food intake and westernized eating habits have adverse associations; in particular, the excessive consumption of red meat, processed meat, and sweetened drinks and the reduction of dairy product intake showed a worsening of lung function, while a diet rich in whole grains, vegetables, fruit, and fish showed a lower risk of newly diagnosed COPD.
The Mediterranean diet is characterized by a high consumption of extra virgin olive oil, fruit, vegetables, fresh produce, nuts and legumes, a low intake of sweetened beverages, red meat and ready-made meals, and a moderate consumption of fish and seafood, poultry, fermented dairy products, and red wine. A relation between adherence to the Mediterranean diet and lung function has been observed over the last decade; a low adherence to the Mediterranean diet was associated with higher prevalence of impaired lung function and lower FVC and FEV₁ values in smokers and in older adults.
Literature shows a protective role of higher adherence to the Healthy Eating Index and the Mediterranean diet for COPD presence and incidence. In a scoping review of 24 studies, 60% reported significant associations between dietary patterns and COPD risk/odds; however, studies examining dietary patterns and COPD patient outcomes produced varied results.
Adhering to the Dietary Approaches to Stop Hypertension (DASH) diet — rich in fruits, vegetables, and grains and low in sodium, fatty meats, and sugar — was inversely associated with the risk of COPD, while mixed results regarding a Mediterranean diet have been reported. A case-control study demonstrated that patients with COPD had a lower adherence to a DASH dietary pattern compared with the control group without COPD.
The interplay between a diet high in processed meat intake and other lifestyle behaviors, such as smoking and an overall unhealthy diet, have been linked to yielding the highest hazard ratio for COPD development. Strong evidence indicates that a Western diet, high consumption of processed meat, and low consumption of fruits, vegetables, and fiber are associated with an increased risk of COPD.
Diets that are rich in fiber content have a positive impact on the gut microbiome; gut microbiota produces short-chain fatty acids (SCFAs) by fermenting dietary fiber, improving gut barrier integrity and regulating the immune system and inflammatory response. This represents an emerging mechanistic pathway through which dietary fiber may influence lung inflammation in COPD, though direct clinical intervention data remain limited.
Deficiencies in vitamin B6 may be associated with a higher risk of frailty in patients with COPD, although no associations have been identified with other vitamins from the B family, including B1, B2, B3, B9, or B12; evidence also supports that a combination of pulmonary rehabilitation with daily oral B12 supplementation in people with moderate-to-severe COPD led to minor improvements in exercise time.
Tobacco-smoke exposure and air pollution enhance oxidant burden and chronic pulmonary and systemic inflammation; oxidant burden in the respiratory tract is increased by tobacco exposure and by the release of reactive oxygen species from neutrophils and macrophages, attracting inflammatory cells into the lungs and inducing inflammatory responses by activating transcription factors like nuclear factor-κB, and enhanced oxidative stress also results in lung-tissue injury by oxidation of proteins, DNA, and lipids.
Dietary intake of nutrients with antioxidant or anti-inflammatory properties, like vitamins and fiber, theoretically could attenuate pulmonary function decline, which can reduce the risk of COPD. Although definitive data are lacking, the available scientific evidence indicates that some foods and nutrients, especially those nutraceuticals endowed with antioxidant and anti-inflammatory properties and when consumed in combinations in the form of balanced dietary patterns, are associated with better pulmonary function, less lung function decline, and reduced risk of COPD.
Nutritional problems are an important part of rehabilitation for COPD patients; COPD patients often present with malnutrition, sarcopenia, and osteoporosis with possible onset of cachexia, with an inadequate dietary intake and a poor quality of life. Both underweight and overweight states are clinically relevant: underweight (low body mass index) is independently associated with increased mortality, while excess adiposity can worsen respiratory mechanics through increased diaphragmatic loading.
Astragalus (Huang Qi) is one of the most frequently used herbs in clinical TCM trials for COPD. A 2023 systematic review and meta-analysis found that astragalus injection combined with ambroxol hydrochloride significantly improved COPD outcomes. Its anti-inflammatory and antioxidant actions reduce oxidative stress in lung tissue. Astragalus appears in both stable COPD and acute exacerbation studies.
Baicalin is a flavonoid glycoside from Scutellaria baicalensis (Chinese skullcap), extensively studied in COPD preclinical models. It attenuates airway inflammation by inhibiting NF-κB activation and reducing TNF-α, IL-6, and IL-8. In cigarette smoke/LPS mouse models, baicalin improved lung function and reduced inflammatory cell infiltration. It is recognized in a 2023 PMC review as having therapeutic potential across multiple lung diseases including COPD.
Patients with COPD have significantly lower skeletal muscle carnosine levels and suffer from elevated exercise-induced acidosis and oxidative stress, creating a mechanistic rationale for BA supplementation. A 12-week double-blind RCT (n=40, 3.2 g/day) confirmed that BA significantly increases muscle carnosine in COPD patients, though improvements in exercise capacity and quadriceps function did not reach statistical significance in this stable cohort. Ongoing larger trials (BASE-TRAIN, BASE-ELECTRIC; n=222) are testing BA as an adjunct to pulmonary rehabilitation.
Cordyceps sinensis (CS) is a traditional Chinese medicinal fungus with substantial clinical data in COPD. A 2019 systematic review and meta-analysis of 15 RCTs (n=1,238 participants) found CS preparations improved lung function, exercise endurance, quality of life, and symptoms in GOLD stage 2–3 stable COPD patients. Evidence quality is limited by lack of placebo controls in many included studies.
Curcumin, the primary bioactive polyphenol in turmeric, has been evaluated in COPD RCTs. A 2025 systematic review and meta-analysis found curcumin (200–500 mg/day) significantly reduced systolic blood pressure and improved FEV1 (SMD=−0.82) compared to placebo in COPD patients. It is recommended as an adjuvant option in this review. Bioavailability is low without enhanced formulations.
DHA is an omega-3 fatty acid showing particularly strong associations with lung function preservation in COPD. A large longitudinal study (n>15,000) found that higher DHA concentrations were specifically associated with improved lung capacity over time. DHA is metabolized to protectins and resolvins that help resolve airway inflammation.
EPA is an omega-3 fatty acid whose serum levels are inversely associated with inflammatory markers (TNF-α) in stable COPD. An RCT in 86 COPD patients showed that combined omega-3/vitamin D/leucine supplementation improved serum EPA levels alongside exercise tolerance. A PMC review identifies EPA among micronutrients protective against COPD progression.
Multiple clinical trials support oral 1,8-cineole (eucalyptol) as an adjunct therapy in COPD, reducing exacerbation frequency and improving lung function. A 6-month, double-blind, placebo-controlled multicenter RCT found significant reductions in exacerbation severity and duration versus placebo. Enteric-coated eucalyptol capsules are approved in Germany for adjunctive inflammatory respiratory treatment.
Multiple animal studies demonstrate Fritillaria alkaloids improve lung function and suppress COPD-relevant inflammation. Imperialine mitigated pulmonary impairment in a cigarette smoke/LPS COPD rat model. A total alkaloid extract from B. Fritillariae pallidiflorae improved pulmonary function, histopathology, and oxidative stress markers in cigarette smoke-induced COPD mice.
Panax ginseng has been used in traditional Chinese medicine for respiratory conditions for millennia and has documented preclinical and early clinical evidence in COPD. Korean Red Ginseng extract and ginsenosides inhibit MAPK/NF-κB/c-Fos inflammatory pathways in lung models. Multiple small controlled clinical trials showed promising effects on COPD symptoms and quality of life, prompting a registered RCT (RMIT University/Austin Hospital).
Ginsenosides, the main active components of Panax ginseng, have demonstrated anti-inflammatory activity via MAPK/NF-κB inhibition in preclinical lung models relevant to COPD. A 2023 PubMed review confirmed their potential in improving COPD, asthma, and pulmonary fibrosis. Korean Red Ginseng-derived ginsenosides have been studied at 6 g/day for COPD-related lung inflammation.
NAC (which converts to L-cysteine in the body) is a proven adjunctive therapy for COPD, reducing exacerbation frequency, improving small airway function, and decreasing airway oxidative stress. Meta-analyses of multiple RCTs consistently show significantly fewer COPD exacerbations with NAC. High-dose NAC (600 mg twice daily) is required for clinical benefit.
GSH levels are depleted in COPD lung tissue and secretions, and oxidative stress is a central disease mechanism. A cohort study in 50 COPD patients found sublingual GSH (300 mg twice daily) alongside standard therapy increased antioxidant enzymes SOD3 and GPX1, though reductions in inflammatory markers IL-8 and TNF-α did not reach statistical significance versus the control group. GSH-S-transferase omega is altered in COPD lung tissue.
Luteolin reduces pulmonary inflammation, oxidative stress, and alveolar damage in COPD preclinical models through NF-κB, Nrf2/HO-1, and MAPK pathway modulation. It is consistently identified as a candidate for COPD management in systematic reviews.
Magnesium deficiency is common in COPD patients. A 2024 systematic review found magnesium supplementation may reduce inflammation levels in COPD patients. Intravenous magnesium sulfate is used in severe acute exacerbations for its bronchodilatory effect. A broad PMC review lists magnesium among micronutrients protective against chronic lung disease.
Adhatoda vasica is documented in pharmacological reviews as having multi-target mechanisms relevant to COPD, including bronchodilatory, anti-inflammatory, and mucolytic activity. Recent 2022–2025 research has specifically highlighted COPD among its mechanistic targets. Traditional use includes chronic bronchitis, the main component of COPD.
NAC is a mucolytic and antioxidant agent extensively studied in COPD. It acts as a glutathione precursor, reducing oxidative stress and mucus viscosity. Multiple meta-analyses and RCTs show high-dose NAC (600 mg twice daily) reduces exacerbation frequency and improves small airway function in stable COPD patients. Evidence is mixed at low doses.
Omega-3 fatty acids (EPA and DHA) have documented anti-inflammatory properties relevant to COPD. A large longitudinal study (n>15,000) found higher omega-3 concentrations were associated with slower lung function decline. Clinical trials in COPD show omega-3 improves muscle health and protein balance. An authoritative PMC review identifies omega-3 fatty acids as protective against COPD progression.
Platycodon has been studied in cigarette smoke-induced chronic bronchitis models relevant to COPD pathology. PG inhibits TLR4/MyD88/NF-κB-driven airway inflammation and reduces mucus hypersecretion and structural airway changes. Evidence is from preclinical studies; no human COPD trials exist.
Quercetin is a dietary flavonoid under clinical investigation for COPD. Preclinical studies show it prevents progression of COPD-like lung disease in mice by inhibiting MMP expression and rhinovirus replication. A safety RCT (BMJ Open Respiratory Research, 2020) established its tolerability in COPD patients. Phase II efficacy trials are ongoing. Definitive clinical efficacy has not yet been established.
Resveratrol is a polyphenol evaluated in COPD for its anti-inflammatory and mitochondrial effects. A 2025 meta-analysis found resveratrol significantly downregulated serum TNF-α and IL-8 in COPD patients. The CARMENS trial (Maastricht University Medical Center) investigated resveratrol's effect on mitochondrial function in COPD. Preclinical rat models also show antioxidant and anti-inflammatory activity in cigarette smoke-induced COPD models.
Rhodiola crenulata (RC) was evaluated in a 12-week randomized double-blind placebo-controlled trial (n=57 stable moderate-to-severe COPD patients). RC 250 mg twice daily significantly improved workload capacity (Δ=+10%, p=0.01) and attenuated FEV1 decline (4.5%, p=0.03) compared to placebo. Salidroside from Rhodiola also demonstrated efficacy in a 2025 COPD polyphenol meta-analysis.
Salidroside, the primary active phenylpropanoid glycoside of Rhodiola, was shown in a 2025 systematic review and meta-analysis of COPD polyphenol RCTs to reduce thrombotic markers (TT, D-D), inflammatory factors (TNF-α), and symptom scores (CAT) (p<0.01) compared to placebo. It was identified as one of only two polyphenols (with curcumin) showing clear efficacy in this meta-analysis.
Selenium is an essential trace element critical for glutathione peroxidase activity, a key antioxidant enzyme in COPD airways. Multiple authoritative reviews identify selenium deficiency as a risk factor for COPD progression. A PMC review of vitamins, minerals, and antioxidants in COPD specifically lists selenium as protective against chronic lung disease. Dietary selenium intake is inversely associated with COPD risk in epidemiological studies.
SPM deficiency has been documented in COPD patients, with evidence of impaired resolution mechanisms contributing to persistent airway inflammation. SPMs attenuate serum amyloid A-driven inflammation and normalize cytokine/chemokine imbalances in COPD models. Reduced LXA4 and other SPM levels have been confirmed in human COPD tissue and sputum samples.
Sulforaphane suppresses TLR2/4-mediated pro-inflammatory cytokine release in macrophages isolated from COPD patients, suggesting therapeutic potential. However, clinical RCTs to date have not shown significant improvements in pulmonary function or systemic inflammation markers in COPD patients.
Tanshinone (from Danshen/Salvia miltiorrhiza) is recommended as an adjuvant treatment option for COPD in a 2025 systematic review and meta-analysis of polyphenol RCTs. Tanshinones are diterpenoid quinones with demonstrated anti-inflammatory and anticoagulant effects in COPD patients, improving coagulation markers and inflammatory cytokines.
Theophylline is a methylxanthine bronchodilator with over 70 years of use in COPD. It inhibits phosphodiesterase (PDE3/4), relaxes airway smooth muscle, and has anti-inflammatory effects including neutrophil suppression in induced sputum. GOLD guidelines permit it only when other bronchodilators are unavailable or unaffordable. Evidence on exacerbation reduction is limited and contradictory.
Vitamin C is a primary antioxidant studied in COPD. A systematic review and meta-analysis specifically on vitamin C supplementation in COPD (PMC, 2022) found it can promote lung function and serum antioxidant levels by decreasing oxidative damage. However, supplementation alone did not show significant effects on FEV1 in a broader 2024 meta-analysis. Its antioxidant role in COPD pathophysiology is well-established.
Vitamin D deficiency is prevalent in COPD patients and linked to increased exacerbation risk and impaired immune function. A systematic review and meta-analysis found vitamin D supplementation alone improved lung function (FEV1, FEV1/FVC) in COPD patients. An RCT in 120 COPD patients showed clinical improvement with calcitriol. Multiple authoritative reviews support vitamin D as protective against COPD progression.
Vitamin D3 (cholecalciferol) is the directly studied form of vitamin D in COPD RCTs. An RCT in 120 COPD patients compared 50,000 IU/day vitamin D3 against calcitriol and placebo, finding clinical improvement in treated groups. A 2024 systematic review confirmed vitamin D3 supplementation improved FEV1 in COPD patients. Deficiency of D3 is strongly associated with increased exacerbation risk.
Vitamin E (primarily alpha-tocopherol) is a fat-soluble antioxidant studied in COPD. A PMC review identifies vitamin E among antioxidants that may protect against COPD progression. A 2024 meta-analysis found vitamin E alone did not significantly improve lung function in COPD, but it contributes to synergistic antioxidant effects with vitamin C in combination. Dietary vitamin E intake is inversely correlated with COPD risk in observational studies.
Zinc deficiency is prevalent in COPD patients and contributes to impaired antioxidant defense and immune function. A PMC review lists zinc among micronutrients with protective roles against chronic lung disease. A 2024 meta-analysis includes zinc in complex micronutrient supplementation that improved FEV1 and FEV1/FVC in COPD patients.
TCM literature documents Aster root for chronic cough, wheezing, and lung deficiency—conditions that overlap clinically with COPD. Modern pharmacological studies on airway inflammation mechanisms are relevant to COPD pathophysiology, though no research has directly studied COPD patients or COPD animal models with Aster root.
Coltsfoot has documented traditional use for chronic obstructive lung conditions including emphysema and silicosis—conditions with overlapping pathophysiology to COPD. It is described in herbal traditions as useful for chronic debilitating lung conditions with persistent cough and trapped mucus. No clinical trials exist.
Echinacea is identified in authoritative herbal sources (Herbal Reality) as a strong antimicrobial herb with a role in acute COPD exacerbations and chronic bronchitis, used to reduce infection-triggered flares. It is widely used in Western herbal medicine for respiratory infections. The German Commission E and ESCOP have approved Echinacea preparations for upper respiratory tract infections, which are a primary trigger for COPD exacerbations.
Elecampane (Inula helenium) has a documented traditional use in COPD, chronic bronchitis, and emphysema. It contains alantolactone and inulin, which stimulate expulsion of thick sticky mucus—vital in COPD where mucus accumulation impairs breathing. Herbal Reality, an authoritative herbalism source, specifically identifies elecampane for COPD and chronic bronchitis.
Garlic is identified by authoritative herbal sources (Herbal Reality) as a strong antimicrobial herb used in acute COPD exacerbations and chronic bronchitis to address infection triggers. Its active constituents allicin and related organosulfur compounds have documented antimicrobial, anti-inflammatory, and expectorant properties. Traditional use in respiratory conditions is long-established across multiple cultures.
Ginger (Zingiber officinale) is identified in authoritative herbal sources (Herbal Reality) as a circulatory stimulant and potent anti-inflammatory that can potentiate expectorants and help reduce airway inflammation in COPD. It has a long history in TCM and Ayurvedic medicine for respiratory conditions. Preclinical evidence supports anti-inflammatory effects on airway tissue.
A PubMed-indexed ethnopharmacological review (2022) documented that I. racemosa has a potential to treat respiratory tract infections including COPD. This is based on traditional documentation and pharmacological plausibility rather than clinical trial data. The plant's expectorant, bronchodilator, and anti-inflammatory properties are the mechanistic basis.
Licorice root (Glycyrrhiza spp.) is one of the eight most frequently used herbs in clinical TCM trials for both stable COPD and acute COPD exacerbations, per a systematic review of 176 TCM clinical trials. It is a demulcent expectorant used in Western herbalism for dry, irritable cough and asthma. Glycyrrhizin and glycyrrhizinic acid have documented anti-inflammatory and antiviral properties.
Lobelia (Lobelia inflata) is a traditional respiratory stimulant and bronchodilator used in Western herbal medicine for COPD, emphysema, and asthma. Herbal Reality identifies it as a powerful bronchodilator that eases breathing and clears mucus. Its active alkaloid lobeline has bronchodilatory properties. It is a Schedule 20 herb in the UK, requiring practitioner prescription due to potency.
Marshmallow root (Althaea officinalis) is classified as a demulcent expectorant by Herbal Reality specifically for COPD, listed alongside liquorice, plantain, and mullein for dry, non-productive, irritable cough in asthma and COPD. Rich in mucilage, it soothes inflamed mucosal surfaces in the respiratory tract. The European Medicines Agency (EMA) supports marshmallow root for irritation of oral and pharyngeal mucosa.
Mullein (Verbascum thapsus) has been used for centuries as a traditional expectorant and respiratory tonic for bronchitis, emphysema, and COPD-like conditions. It is recognized by herbalists as a stimulative expectorant that loosens thick mucus. Authoritative herbal resources including Herbal Reality identify mullein for COPD/emphysema support, though clinical RCT evidence is absent.
Yuan Zhi has been used in TCM as an expectorant and anti-inflammatory herb relevant to obstructive pulmonary disease. A 2025 preclinical study examined PT water extract in a cigarette smoke-induced COPD mouse model, finding improved lung function and reduced inflammation. No human COPD trials have been published.
A 2025 Frontiers in Microbiology/PMC study specifically investigated Polygala tenuifolia water extract in a COPD animal model, finding anti-inflammatory effects and microbiome/lung epithelial benefits. The Chinese Pharmacopoeia lists anti-asthmatic applications. Human COPD trials are lacking.
Thyme (Thymus vulgaris) is a well-established traditional remedy for spasmodic cough, bronchitis, and chronic airway conditions including COPD. Herbal Reality identifies it as a warming expectorant and strong antimicrobial herb with a role in acute COPD exacerbations. Its active constituent thymol has documented mucolytic and antispasmodic properties. The German Commission E has approved thyme leaf for bronchitis.
Go back